Cargando…
2813. Impact of a Recent Change in Tobramycin Breakpoints (CLSI) on the Proportion of Pseudomonas aeruginosa Clinical Isolates that are Multidrug-Resistant: CANWARD, 2016 to 2021
BACKGROUND: Pseudomonas aeruginosa (PA) is an important nosocomial pathogen. In 2023, tobramycin (TM) susceptibility breakpoints for PA were lowered (from ≤4 to ≤1 µg/mL) by the Clinical and Laboratory Standards Institute (CLSI). The purpose of this study was to evaluate whether this change will res...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679049/ http://dx.doi.org/10.1093/ofid/ofad500.2424 |